Dr. Randi Isaacs' upcoming presentation at the KidneyCAN 7th Annual Kidney Cancer Research Summit highlights Werewolf's innovation in conditionally activated therapeutics, which could enhance ...
In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results